Showing posts with label SSRIs. Show all posts
Showing posts with label SSRIs. Show all posts

Tuesday, May 22, 2018

Medical Malpractice Verdict Seen As Powerful Message To Mental Health Providers

PR newswire

News provided by
The Mark D Truskie Foundation
May 21, 2018, 08:28 ET

COAROPOLIS, Pa., May 21, 2018 /PRNewswire/ -- Stanley D. Truskie, President of the Mark D. Truskie Foundation, issued a statement that the $2 million verdict on Wed, May 16, 2018 in favor of him and his wife, Marianne, as a result of the death of their son Mark, is a decision that will send a powerful and important message to the psychiatric community, and to psychiatric clinics throughout the country. Mark lived at home with the Truskies and died at the age of 46.

After Mark's death on November 12, 2013, the Allegheny County coroner determined that he died from toxic levels of Celexa and Cloziral, two medications used to treat his mental condition. Mark's psychiatrist, Dr Grace Huang of the Staunton Clinic in Sewickley, PA, prescribed both medications.

"We were able to prove that Huang and the Staunton Clinic ignored two critically important FDA Safety warnings regarding Celexa, which is a medication known to cause sudden cardiac death when prescribed above certain doses," stated attorney Tyler Smith, representing the Truskie family.

"The evidence demonstrated that Huang and the Staunton Clinic prescribed Celexa to Mark at twice the allowable dose without informing Mark or the Truskies of the FDA warnings, or informing them about simple and safe tests that could have been used to protect Mark from the increased risk of harm caused by his medications," Smith added.

Truskie believes there are several valuable lessons psychiatrists and psychiatric clinics should learn from this important case including the following:
  • Patients, and caregivers, must be informed of the side effects of the psychiatric medications being prescribed;
  • Warnings from physician instructions accompanying the medications, and FDA warnings regarding the prescribed medications must be communicated to patients, and caregivers;
  • Treating psychiatrists should ensure that periodic health exams are scheduled and completed for their patients, such as heart monitoring, drug concentration measurements, liver enzyme testing and other appropriate tests, especially when multiple psychiatric medications with known, dangerous side effects are being prescribed;
  • Referrals to appropriate specialists such as cardiac physicians, metabolic specialists, lipidologists, and nutritional counselors should be incorporated into the treatment plan of the patient;
  • Patients/caregivers should be alerted to signs and symptoms such as toxicity, heart arrhythmia, and other life-threatening conditions when such side effects are indicated by the medications being prescribed, and further, they should be instructed on what to do in an emergency; and
  • Managers and administrators of psychiatric clinics must ensure that policies and procedures are in place to guarantee these standard of care practices are in place and followed.
In closing, Truskie stated, "This award will help fund the Mark D. Truskie Foundation which we started in Mark's name to help protect the health and safety of those dealing with mental health problems."

Contact:
Stanley D. Truskie, Ph.D.
412-979-8146
195605@email4pr.com
www.markdtruskiefnd.org

SOURCE The Mark D Truskie Foundation

Related Links

http://www.markdtruskiefnd.org

Thursday, November 19, 2015

Psychiatric Drugs Account For Almost 10% of Adult, Prescription Drug Emergency Room Visits

Makes you wonder how we could save a whole lot of Real money in health care costs, no?

madinamerica

Adverse effects from psychiatric drugs account for almost one in ten adult emergency room visits related to prescription medications and one in five of these visits result in hospitalization.
“Considering the growing exposition to antipsychotics in the general population and the increasing off-label use of antipsychotics, the findings of this study urge providers to prescribe antipsychotics cautiously and only after exploring the feasability of using alternative treatments,” Dr. Lucien Roulet, wrote in a commentary to be published in the journal ofEvidence-Based Mental Health.
More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication, but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials. A 2014 study, published in JAMA Psychiatry, analyzed emergency department records from 2009 to 2011 to attempt to estimate the frequency and seriousness of adverse drug events related to the use of psychiatric drugs.
As a result of this first-of-its-kind analysis, researchers identified several psychiatric drug prescriptions that lead to a substantial percentage of emergency room visits. Antipsychotics and antidepressants were the leading cause of emergency room visits for adverse effects from psychotropic drugs. Together, they accounted for nearly two-thirds of all such visits, with antipsychotics making up 31.3% and antidepressants 30.5%. Shockingly, the insomnia Z-drug,Zolpidem, accounted for more than one in five (21%) of all psychiatric drug related emergency room visits on its own.
“These results should incite providers to take a critical look at the trend in prescribing Z-drugs and to only prescribe the latter after considering non-pharmacological measures to manage insomnia, especially in adults 65 years or older.”
The prevalence of mental health problems is estimated to be high worldwide, with a large number of patients exposed to psychiatric medications in developed countries. The efficacy of psychopharmacological treatments has been called into question, however, and this study suggests that providers should also carefully assess the risk of adverse effects before they decide to prescribe psychiatric medications.
“In conclusion, this proper pharmacoepidemiological study provides strong evidence data to balance the current process of medicalisation of psychopathology under both patients and society pressure.”
Hampton, L. M., Daubresse, M., Chang, H. Y., Alexander, G. C., & Budnitz, D. S. (2014). Emergency department visits by adults for psychiatric medication adverse events. JAMA psychiatry, 71(9), 1006-1014. (Full Text)
Roulet, L. (2015). Identifying psychiatric medications causing high numbers and rates of emergency department visits among US adults. Evidence Based Mental Health, 18(4), e6-e6. (Abstract)




Tuesday, March 31, 2015

Germanwings Pilot Reportedly Had Antidepressants - Many Banned By FAA


The link between mass shootings at schools and antidepressants has been long established. 

Looks like we now have mass murder by airline pilot linked to these drugs.

Germany's Die Welt has reported that the German pilot who apparently deliberately crashed a commercial passenger plane had antidepressant drugs in his home, according to CNN. The US Federal Aviation Administration has banned US pilots from taking many SSRI antidepressants.
"Die Welt, a German newspaper, cited an unidentified senior investigator who said [co-pilot Andreas] Lubitz suffered from a severe 'psychosomatic illness' and German police seized prescription drugs that treat the condition," stated CNN. "Lubitz suffered from a 'severe subjective burnout syndrome' and from severe depression, the source told Die Welt. The New York Times also reported that antidepressants were found during the search of his apartment. CNN has not been able to confirm the reports."
The articles also mentioned that Lubitz apparently had been recently having unusual vision problems, which are a recognized potential side effect of antidepressants.
A US Federal Aviation Administration Accepted Medications list provided by the company Pilot Medical Solutions states that, "Single-use Anti-Depressants such as: Celexa (Citalopram Hydrobromide), Lexapro (Escitalopram Oxalate), Prozac (Fluoxetine Hydrochloride) or Zoloft (Sertraline Hydrochloride) are approved by the FAA on a case by case basis only. Approval is very difficult, and does not permit applicants to be approved by an AME or even the FAA in Oklahoma City. All other psychiatric medications, including other SSRI's such as Luvox (Fluvoxamine), Paxil (Paroxetine), Viibryd (Vilazodone), are not acceptable to the FAA."
The FAA's website confirms that, "The FAA has determined that airmen requesting first, second, or third class medical certificates while being treated with one of four specific selective serotonin reuptake inhibitors (SSRIs) may be considered. The Authorization decision is made on a case by case basis."
According to a 2011 presentation on the International Civil Aviation Organization website, the Convention on International Civil Aviation has developed a similar recommendation that pilots taking antidepressants should be deemed "unfit" to fly, except in specially evaluated cases.
In a 2010 article in the Huffington Post, MIA Blogger Peter Breggin lamented that the FAA had recently lifted its absolute ban on antidepressants and was instead providing a "Medication Guide to patients and their families that warns about dangerous drug-induced reactions including suicide, violence and a variety of unexpected negative behaviors." Breggin warned that, "The FAA should reverse its ruling before it's too late and hundreds of lives are lost when a pilot becomes impulsive, suicidal or violent--or just loses his sharpness--under the influence of antidepressant medication."
FAA Accepted Medications (Pilot Medical Solutions, Inc website, Updated 2/9/15)
Recent changes to Annex 1 Medical Standards and Recommended Practices(International Civil Aviation Organization presentation)

--Rob Wipond, News Editor

This entry was posted in Antidepressants, Featured News, In the News, Violence and tagged Google News. Bookmark the permalink.

RELATED POSTS


Thank You Mr Wipond and MIA.

Thursday, August 21, 2014

Increased Risk of Bone Fracture From SSRI Antidepressants

madinamerica;



August 21, 2014

“Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk,” reported researchers in a mini-review of the scientific literature published in Endocrine.
The Belgian University of Liège researchers expressed concern that SSRIs are often prescribed to older adults at high risk for bone fractures. The level of risk differs “depending on dose, exposure duration, time of exposure, age, or sex,” they wrote. “However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis.”
Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome(Bruyère, Olivier and Reginster, Jean-Yves. Endocrine. August 5, 2014. DOI 10.1007/s12020-014-0357-0)

Monday, December 23, 2013

SSRIs Cause Epilepsy In Rats

Well What D'ya Know? 

More of the Direct Effects (that's right, the term Side-Effect is BS to cover for the fact that if you hadn't been BS-ed into ingesting the drug in the first place, you Wouldn't be suffering the Direct Effects of that drug to begin with) bubble to the surface, kind of like the remains that belch up out of the La Brea Tar Pits from time to time.

via Mad In America;
SSRIs Cause Epilepsy In Rats


December 16, 2013
Researchers from Australia find that chronic treatment with SSRIs significantly increases the rate of epileptogenesis in rats.  Although SSRIs are commonly prescribed to people with epilepsy due to its high comorbidity with depression, they say, no previous studies have investigated the effects of SSRIs on epileptogenesis.  Results appeared online in the journal Neurobiology of Disease.
Cardamone, L., Salzburg, M., Koe, A., Ozturk, E., O’Brien, T., Jones, N.; Chronic antidepressant treatment accelerates kindling epileptogenesis in rats. Neurobiology of Disease. Online December 7, 2013.
This entry was posted in Antidepressants, Featured News, In the News, Psychiatric Drugs, Research byKermit Cole. Bookmark the permalink.

Related Posts:


Monday, June 10, 2013

SSRIs Can Impair New Learning About Anxiety


Mad In America has;

June 8, 2013

Researchers from Columbia University and the New York State Psychiatric Institute test the behavioral effects of SSRIs on Pavlovian fear conditioning in rats, and propose a model by which acute SSRI administration alters neural activity in the amygdala and hippocampus in a way that reduces anxiety symptoms but impairs the ability to learn new responses anxiety. Results appear in this month’s Neuroscience.
Burghardt, N., Bauer, E.; Acute and Chronic Effects of SSRI Treatment on Fear Conditioning: Implications for Underlying Fear Circuits. Neuroscience. Online June 1, 2013